腹腔热灌注联合全身静脉化疗在卵巢癌治疗中的不良反应评价
DOI: 10.3971/j.issn.1000-8578.2019.19.0324
Keywords: An Analysis of 820 Cases,Influences of FGF3 and FGF10 on Migration and Invasion of Human Ovarian Cancer SKOV3 Cells and Relation Between These Influences and Wnt/β-catenin Signaling Pathway,Afatinib Sensibilizes Multidrug-resistant Human Ovarian Cancer Cells to Adriamycin and Related Mechanisms,Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer,Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a,Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer,Multi-line Treatment Combined Apatinib with Toptecan for Platinum-resistant Recurrent Ovarian Cancer: Two Cases Report,Review of Molecular Subtyping of Ovarian Cancer and Its Clinical Application,Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Gastric Cancer Peritoneal Carcinomatosis: A Systemic Analysis,卵巢癌血清新型肿瘤标志物研究与应用现况,Expression and Clinical Significance of LncRNA KCNQ1OT1 in Ovarian Cancer Tissues,Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer
Abstract:
摘要 目的 评价肿瘤细胞减灭术后行腹腔热灌注联合全身静脉化疗在卵巢癌治疗中的不良反应及其对患者生存期的影响。方法 选取163例卵巢癌患者作为研究对象,所有患者均行肿瘤细胞减灭术并按照治疗方法分为观察组(47例)与对照组(116例),观察组为术后行腹腔热灌注联合全身静脉化疗,对照组为术后单纯全身静脉化疗。观察两组患者的不良反应发生情况,并对所有患者进行术后随访。 结果 观察组低蛋白血症发生率高于对照组,而白细胞减少、血小板下降、腹胀及腹痛发生率低于对照组(P<0.05),其余不良反应差异无统计学意义。当患者热灌注次数>2次时D2聚体升高、低钙血症、血糖升高和恶心呕吐的发生率升高(P<0.05)。两组患者总生存率无显著差异,观察组无贫血或轻度贫血患者生存情况优于重度贫血患者(P<0.05),其余不良反应的发生对患者整体生存率没有显著影响。结论 卵巢肿瘤细胞减灭术后行腹腔热灌注化疗联合静脉化疗并不会增加不良反应、尤其是严重不良反应的发生,但存在低蛋白血症发生率高的特点
Full-Text